Pol Hernández Lladó

My research is focused on the development of new molecular tools to interrogate biology, with the aim to discover new therapeutic targets to treat metabolic diseases such as diabetes. Currently, I am developing a molecular toolkit for the selective labelling of endogenous GLUT4 to study of its trafficking and map its interactome, in collaboration with Novo Nordisk.

GLUT4 plays a critical role in glucose transport, mediating the increased glucose uptake into muscle and adipose tissue in response to insulin and exercise. Disruption in GLUT4 trafficking is a hallmark of type 2 diabetes and is linked to obesity. My research aspires to identify new molecular targets that can modulate this system, offering promising avenues for therapeutic intervention. These findings will help pave the way for the development of GLUT4-targeted therapies that alter its distribution, potentially leading to new treatments for metabolic disorders.